Identification of Lactobacillus Fermentum Strains with Potential against Colorectal Cancer by Characterizing Short Chain Fatty Acids Production, Anti-Proliferative Activity and Survival in an Intestinal Fluid: In Vitro Analysis
1Biomedical Technology and Cell Therapy Research Laboratory-Departments of Biomedical Engineering, Physiology, and Artificial Cells and Organs Research Center, Faculty of Medicine, McGill University, Canada
- *Corresponding Author:
- Satya Prakash
Department of Experimental Medicine
Faculty of Medicine, McGill University, Canada
Email: [email protected]
Received Date: May 28, 2015 Accepted Date: July 06, 2015 Published Date: July 09, 2015
Citation: Kahouli I, Malhotra M, Tomaro-Duchesneau C, Rodes LS, Aloui-Jamali MA, et al. (2015) Identification of Lactobacillus Fermentum Strains with Potential against Colorectal Cancer by Characterizing Short Chain Fatty Acids Production, Anti-Proliferative Activity and Survival in an Intestinal Fluid: In Vitro Analysis. J Bioanal Biomed 7:104-115. doi:10.4172/1948-593X.1000132
Copyright: © 2015 Kahouli I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The use of probiotics as preventive agents in colorectal cancer (CRC) was widely suggested in many clinical and pre-clinical studies and often linked to affecting short chain fatty acids (SCFA) in the gut. However, the understanding of fatty-acid-producing activity of certain probiotics and their preventive and anti-cancer potential remains incomplete. Here, L. fermentum strains were investigated for a number of features that make them good candidates for use in CRC treatments. Using cell free extracts, L. fermentum NCIMB -5221, -2797 and -8829 were first compared based on SCFAs production and anti-proliferative activity against Caco-2 colon cancer cells. The corresponding SCFAs synthetic formulations, similar to the ones produced by the bacteria, were prepared then compared with the latter to determine the role an efficacy of naturally produced SCFAs in inhibiting the proliferation of colon cancer cells. Later, the bioactivity and stability of L. fermentum bacteria in a simulated intestinal fluid (SIF) were determined. Results showed that L. fermentum NCIMB -5221 and -8829 were the most potent in producing SCFAs, in particular, acetic (192.3 ± 4 mg/L minimum), propionic (69.2 ± 1.6 mg/L minimum), and butyric (35.4 ± 2.9 mg/L minimum) acids and were observed to better inhibit the growth of Caco-2 cells (53.4 ± 1.6%, 72 h, p=0.021) in comparison with L. acidophilus ATCC 314. They also showed resistance to SIF (16.3 ± 1.9% minimum, 72 h, p=0.006) and produced SCFAs in SIF at concentrations high enough to significantly inhibit Caco-2 proliferation (74.73 ± 2.1%, 72 h). Potentially, based on characteristics related to bacterial cell survival and SCFA production, and anti-proliferative activity, certain L. fermentum could be considered as biotherapeutic agent against CRC.